Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Invested Capital (2020 - 2025)

Historic Invested Capital for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $494.7 million.

  • Apellis Pharmaceuticals' Invested Capital rose 10864.83% to $494.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $494.7 million, marking a year-over-year increase of 10864.83%. This contributed to the annual value of $228.5 million for FY2024, which is 1748.81% up from last year.
  • Apellis Pharmaceuticals' Invested Capital amounted to $494.7 million in Q3 2025, which was up 10864.83% from $156.3 million recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Invested Capital peaked at $494.7 million during Q3 2025, and registered a low of -$334.4 million during Q2 2022.
  • Moreover, its 5-year median value for Invested Capital was $228.5 million (2024), whereas its average is $192.3 million.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Invested Capital tumbled by 16097.15% in 2021 and then skyrocketed by 79479.85% in 2022.
  • Apellis Pharmaceuticals' Invested Capital (Quarter) stood at $198.7 million in 2021, then dropped by 14.49% to $169.9 million in 2022, then rose by 14.51% to $194.5 million in 2023, then increased by 17.49% to $228.5 million in 2024, then skyrocketed by 116.48% to $494.7 million in 2025.
  • Its Invested Capital was $494.7 million in Q3 2025, compared to $156.3 million in Q2 2025 and $164.2 million in Q1 2025.